What is ResMed's EPS (diluted)?

ResMed (RMD) reported EPS (diluted) of $2.74 in Q1 2026.

How has ResMed's EPS (diluted) changed year-over-year?

ResMed's EPS (diluted) increased by 10.5% year-over-year, from $2.48 to $2.74.

What is the long-term trend for ResMed's EPS (diluted)?

Over 3 years (2022 to 2025), ResMed's EPS (diluted) has grown at a 21.4% compound annual growth rate (CAGR), from $5.31 to $9.51.

What does EPS (diluted) mean?

Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

ResMed RMD EPS (Diluted)

Discontinued — last reported Q3 '26

EPS (Diluted) at other companies

Eli LillyLLY

$8.26+170%

InogenINGN

-$0.30-20.0%

Five Point Holdings, Inc.FPH

$0.00-100%

Inspire Medical SystemsINSP

-$0.39-490%

Viemed Healthcare, Inc.VMD

$0.060.0%

LivaNovaLIVN

$0.40+107%

Other financials

Income statement

See full

Revenue$1.4B+10.8%

Gross profit$891.0M+16.3%

Operating income$499.8M+17.3%

Net income$398.7M+9.2%

Balance sheet

See full

Cash & equivalents$1.7B+78.0%

Total debt$1.1B+29.8%

Total equity$6.5B+17.1%

Total assets$8.8B+16.1%

Cash flow

See full

Operating cash flow$554.1M-4.2%

CapEx$33.7M+61.8%

Free cash flow$520.5M-6.7%

Valuation

See full

Market cap$28.27B-19.1%

Enterprise value$27.71B-19.8%

P/E18.6×-6.3×

P/S5.1×-1.7×

Profitability

See full

Gross margin61.6%+2.8pp

Operating margin34.2%+2.1pp

Net margin27.4%+1.3pp

FCF margin31.7%+0.4pp

Returns & leverage

See full

Return on equity25.2%-0.6pp

Debt / equity0.2×0.0×

Current ratio3×-0.4×

Where this comes from

Reported directly by ResMed in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: ResMed’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about ResMed's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ResMed's EPS (diluted)?: ResMed (RMD) reported EPS (diluted) of $2.74 in Q1 2026.
How has ResMed's EPS (diluted) changed year-over-year?: ResMed's EPS (diluted) increased by 10.5% year-over-year, from $2.48 to $2.74.
What is the long-term trend for ResMed's EPS (diluted)?: Over 3 years (2022 to 2025), ResMed's EPS (diluted) has grown at a 21.4% compound annual growth rate (CAGR), from $5.31 to $9.51.
What does EPS (diluted) mean?: Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.